Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
C1QTNF9B antisense RNA 1 (C1QTNF9B-AS1), also referred to as PCOTH or Prostate collagen triple helix protein, is a **long non-coding RNA (lncRNA)**. Multiple sources confirm its classification as an RNA gene, not a receptor, enzyme, or classic druggable protein target. It is expressed in various tissues, including the prostate and testis, and is predicted to have functions related to the extracellular matrix or as a structural RNA. Some studies suggest a link to prostate cancer cell growth and potential regulatory roles, but **there is little direct evidence that C1QTNF9B-AS1 functions as a therapeutic target, receptor, or enzyme**. It is not currently associated with known pharmacological modulators or established clinical biomarkers. Existing references conflate protein-coding genes (such as C1QTNF9B) and the lncRNA (C1QTNF9B-AS1), but the target described in your query matches the lncRNA, not a classic protein target[2][4][5][6][7]. Therefore, there is a conceptual error in treating "PCOTH" or "C1QTNF9B-AS1" as a classic target; it should be cataloged as a long non-coding RNA, not a protein or receptor.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on C1QTNF9B antisense RNA 1 (C1QTNF9B-AS1).